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Abstract
Bayesian modelling for cost-effectiveness data has received much attention in both
the health economics and the statistical literature in recent years. Cost-effectiveness
data are characterised by a relatively complex structure of relationships linking the
suitable measure of clinical benefit (e.g. QALYs) and the associated costs. Simplifying
assumptions, such as (bivariate) normality of the underlying distributions are usually
not granted, particularly for the cost variable, which is characterised by markedly
skewed distributions. In addition, individual-level datasets are often characterised by
the presence of structural zeros in the cost variable.
Hurdle models can be used to account for the presence of excess zeros in a distribution
and have been applied in the context of cost data. We extend their application to cost-
effectiveness data, defining a full Bayesian model which consists of a selection model
for the subjects with null costs, a marginal model for the costs and a conditional
model for the measure of effectiveness (conditionally on the observed costs). The
model is presented using a working example to describe its main features.
Key words: Cost-effectiveness models; Bayesian mixture models.
1 Introduction
Modelling for cost-effectiveness data has received much attention in both the health economics and
the statistical literature in recent years [1, 2], increasingly often under a Bayesian statistical approach
[3, 4, 5, 6]. From the statistical point of view, this is an interesting problem because of the generally
complex structure of relationships linking a suitable measure of clinical benefit (e.g. QALYs) and the
associated costs. In addition, simplifying assumptions, such as (bivariate) normality of the underlying
distributions are usually not granted, particularly for the cost variables.
In fact, costs are typically characterised by a markedly skewed distribution, which is generally due
to the presence of a small proportion of individuals incurring large costs. To accommodate this feature,
several models have been suggested and implemented. Among them, the most popular are probably
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represented by the log-Normal and Gamma distributions [7, 8], which are well suited to describe right
skewed data.
However, in addition, individual-level datasets (such as those collected in clinical trials) are often
characterised by the presence of structural zeros in the cost variable: this amounts to observing a
proportion of subjects for whom the observed cost is equal to zero. Under these circumstances, the use
of log-Normal or Gamma models becomes impractical, since these distributions are defined for strictly
positive arguments. A simple solution is to add a small constant ǫ to the entire set of observed values
for the cost variable, thus artificially re-scaling it in the open interval (0,∞) [9]. While very easy to
implement, this strategy is potentially problematic, since the results are likely to be strongly affected
by the actual choice of the scaling parameter ǫ. In particular, there is no real guidance as to “how
small” the value ǫ should be in order to minimise its influence on the economic results.
Alternatively, it is possible to use specific strategies to model data including structural zero costs
that overcome this issue, e.g. hurdle models [10]; extensive treatment of this topic in the health
economics literature is given in [9, 11, 12], while applications include [13, 14]. In a nutshell, the idea is
to build a “selection” model that predicts the probability of a given individual being associated with
a null cost; this is typically done using a logistic regression as a function of a set of relevant covariates.
Then, for the individuals incurring a positive cost, a regression model is fitted to estimate the average
cost, which effectively is a mixture of the two components.
With the notable exception of [15] (who applied a bivariate Normal model to estimate survival
and partially measured costs), hurdle models have been mainly used to either estimate the effect of
relevant covariates or to predict future costs, without explicit reference to a measure of clinical benefit.
The evaluation of the costs, however, is only one side of a comprehensive cost-effectiveness analysis,
which needs to simultaneously account for the expected clinical benefits as well. As mentioned earlier,
because costs and benefits are typically correlated, it is necessary to produce a multivariate model that
can cater for this situation.
In this paper we aim at extending the two-parts model to produce a general framework able to
account for: a) structural zero costs; and b) correlation between costs and clinical benefits. We take
advantage of the flexibility of Bayesian models, which allow to specify several components that can
then be linked to induce correlation among the different modules. We consider three components; the
first one is a selection model that predicts the probability that each individual is associated with zero
costs. The second module is a marginal model for the costs, which is expressed as a mixture of two
components, depending on the observed value for the costs. Finally, the third module is a conditional
model for the variable of effectiveness, conditionally on the observed value for the costs.
The paper is structured as follows: first in section 2 we set out our modelling framework. We then
present the data and specific model used to analyse a case study in section 3, discussing the specific
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model in 3.1 and the results in 3.2. Section 4 reviews the main conclusions.
2 Modelling framework
Consider a dataset D including information on a set of n individuals. This may arise in the case of
a randomised clinical trial, or from observational data obtained from registries of clinical practice.
We assume that, for each subject, D contains at least two variables (e, c) measuring suitably defined
clinical benefits and the associated costs. As we will show in the following, it is helpful to assume that
the study also records some additional information at the individual level, e.g. age, sex or potential
co-morbidities. We also note that, even in the case of RCTs where these variables are not essential in
the estimation of the treatment effects (by virtue of randomisation), they are usually measured and
included in the final dataset.
For each intervention or treatment t = 0, . . . , (T − 1) under consideration, we can define a subset
Dt with sample size nt, so that D =
⋃
tDt and n =
∑
t nt. We partition the observed data as
Dt = (D
null
t ∪D
pos
t ), where D
pos
t includes the n
pos
t individuals generating a positive cost. Consequently,
nnullt = nt − n
pos
t is the number of subjects with structural zero cost. Without loss of generality, we
assume in the following that only two interventions are being considered: t = 0 is some standard (e.g.
currently recommended or applied by the health care provider) and t = 1 is a new intervention being
suggested to potentially replace the standard.
2.1 Selection model for c = 0
We estimate the probability that each individual has a null observed cost, as a function of J relevant
covariates. For each subject in i = 1, . . . , nt, we define an indicator dit taking value 1 if that individual
is observed to have a null cost, and 0 otherwise. We model this variable as
dit ∼ Bernoulli(πit)
logit(πit) = β0t +
J∑
j=1
βjtZ
t
ij , (1)
where πit indicates the required probability. Both for computational and practical reasons (which we
describe later), it generally helps to centre the covariates, i.e. for each treatment group, instead of the
originally observed covariate Xtj we include in (1) its centred version Z
t
ij = X
t
ij − E[X
t
j ]. Of course
this construction implies that E[Ztj ] = 0.
Within the Bayesian framework, the coefficients βt = (β0t, β1t, . . . , βJt) are given suitable probabil-
ity distributions. One simple choice is to use independent minimally informative Normal distributions
(i.e. centred on 0 and with large variance), but of course other choices are possible. This, however,
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does not normally impact to a (too) large extent on the results, especially in presence of (at least)
moderately large datasets.
Nevertheless, it is worth noting that, in cases where the number of subjects with structural zeros is
very small, separation (i.e. the fact that a linear combination of the predictors is perfectly predictive
of the outcome) is potentially an issue. A possible solution is to model the coefficients using Cauchy
priors centred on 0 and with a small scale parameter [16].
Under the assumptions specified above, the quantity
pt =
exp(β0t)
1 + exp(β0t)
represents the estimated overall probability of having a null cost for the “average” individual (i.e.
one with the values of the covariates set to 0, their mean). Sub-group analyses would be possible by
selecting the combination of modalities for the covariates that define the required individual profile.
Moreover, the model in (1) can be extended to include individual structured (“random”) effects, for
example in the case of clustering over time in repeated measurement data.
2.2 Marginal model for the costs
In the second module, we model the observed costs by specifying a single distributional form for the
two components (subjects with null or positive costs). Nevertheless, this distribution is indexed by two
different sets of parameters θt = (θ
null
t , θ
pos
t ), which depend on the value taken by dit. In particular,
we have that
cit | dit ∼
{
p(cit | dit = 1) = p(cit | θ
null
t ), for i ∈ D
null
t
p(cit | dit = 0) = p(cit | θ
pos
t ), for i ∈ D
pos
t .
At this stage, we can choose any suitable distributional assumption for p(cit | dit).
2.2.1 Gamma model
For example, we can model the costs for both components using a Gamma distribution
cit | dit ∼ Gamma (ηt,dit , λt,dit) ,
where the nested index dit takes values 0,1 for patients with positive and null costs respectively. Thus,
θ
pos
t = (ηt0, λt0) and θ
null
t = (ηt1, λt1), where, for s, t = 0, 1, ηts is the shape, λts is the rate of the
Gamma density and, by definition,
ψts =
ηts
λts
and ζts =
√
ηts
λ2ts
(2)
are, respectively, the mean and the standard deviation of the cost distribution, on the natural scale.
It is possible to encode the required distributional assumptions by choosing suitable priors for θnullt ;
in particular, we require that the distribution of costs must be identically 0 for all the patients with
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observed null cost. But if we choose ηt1 = w and λt1 = W , with 0 < w << W (e.g. w = 1 and
W = 10000), then ψt1 → 0 and more importantly ζt1 → 0 to an even faster rate of convergence. Thus,
effectively, for the patients with observed null value, the cost is estimated to be identically 0 — and as
a matter of fact, this prior is so informative that no amount of evidence can modify it in the posterior.
As for the patients with positive costs, we need to assume a non-degenerate prior on θpost to
obtain a reasonable model. In this case, it is easier to encode any available information on the
normal scale parameters (ψt0, ζt0), rather than on the shape and rate of the Gamma distribution,
which are less straightforward to interpret and give a prior to. Just as an example, one may assume
ψt0 ∼ Uniform(0, Hψ) and ζt0 ∼ Uniform(0, Hζ) for suitably selected values Hψ, Hζ . Inverting the
deterministic relationships in (2) it is easy to derive
ηt0 = ψt0λt0 and λt0 =
ψt0
ζ2t0
and thus the distributions selected for (ψt0, ζt0) automatically imply the priors for (ηt0, λt0). Notice
that these will in general not be vague at all, even in case the priors for (ψt0, ζt0) are chosen to be
minimally informative, as in the example below — in fact by assuming a flat prior on the natural
scale parameter, we are implying some information on the orginal parameters of the assumed Gamma
distribution.
2.2.2 Log-Normal model
The above construction allows us to use a single distributional form to model the costs in both sub-
groups and we can use the same rationale to encode different distributional assumptions. For example,
we could use a log-Normal model to describe sampling variations in the observed costs. In this case,
we have that
cit | dit ∼ log-Normal (ηt,dti , λt,dit) ,
where ηts and λts are now the population average and standard deviation of the cost on the log
scale, respectively. By the basic properties of the log-Normal distribution the mean and the standard
deviation of the cost on the natural scale can be computed for each sub-group s = 0, 1 as
ψts = exp
(
ηts +
λ2ts
2
)
and ζts =
√
(exp(λ2ts)− 1) exp (2ηts + λ
2
ts). (3)
Setting ηt1 = −W and λt1 = w for 0 < w << W (e.g. w = 10 and W = 1000) implies that for
the individuals in Dnullt the cost on the natural scale is effectively 0 with no substantial variability.
Conversely, in a similar fashion to what shown above, we can define the non-degenerate prior for the
individuals with positive costs on the natural scale, rather than on the original parameters on the log
scale; for instance, one could again use Uniform priors for (ψt0, ζt0) and then invert the relationships
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in (3) to obtain
ηt0 = log(ψt0)−
1
2
log
[
1 +
(
ζt0
ψt0
)2]
and λt0 =
√√√√log
[
1 +
(
ζt0
ψt0
)2]
and thus induce the priors for (ηt0, λt0).
2.2.3 Computation of the average cost
Of course none of the distributional assumptions discussed above are essential and it is possible to
express the available prior information in different ways and using other parametric models. Neverthe-
less, the general framework still applies and one can use a single distribution to represent the observed
costs in both the components of the population, simply by cleverly modelling the parameters.
In addition, regardless on the underlying marginal model, once the two components of ψt =
(ψt0, ψt1) have been estimated, it is then possible to derive the overall average cost in the population
by computing the weighted average
µct = (1− pt)ψt0 + ptψt1 (4)
= (1− pt)ψt0,
where the weights are given by the estimated probability associated with each of the two classes. In
effect, the population average cost is obtained by down-weighting the estimated average for Dpost , to
account for the presence of the structural zeros. The weights of the mixture are informed by the
selection model.
2.3 Conditional model for the measure of clinical benefit
The final module consists in modelling the measure of clinical benefit e so that correlation between the
two dimensions of the health economic evaluation is accounted for. One possible way of doing so is to
factorise the joint distribution p(e, c | θt) in the product of a marginal and a conditional distribution.
Intuitively, it is easier to think of this factorisation in terms of p(e | θt)p(c | e, θt), i.e. assuming
that the observed costs somehow depend on the value taken by the measure of effectiveness. This
construction has been used for example in [3].
However, because we are merely modelling a probabilistic structure (i.e. we are not claiming any
causal relationship), it is equally reasonable to factorise the joint distribution in terms of a marginal
density for the costs and a conditional density for the benefits given the costs, i.e. p(e, c | θt) = p(c |
θt)p(e | c, θt) — in this sense we refer to the model of section 2.2 as marginal and to the one in the
current section as conditional.
The distribution p(e | c, θt) is chosen according to the nature of the effectiveness variable. For
example, if e were expressed in terms of QALYs over a long period of time, it should be a continuous
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density defined in R+. But, as discussed in [7], whatever this choice one can always represent its mean
(i.e. the conditional average effectiveness, given the costs) through a regression model
g(φit) = ξt + γt(cit − µct) (5)
defined in terms of a suitable link function g(·). The form of the link function obviously depends on
the scale in which φit is defined, e.g. if φit were modelled on the natural scale of e, then g(·) would be
the identity function.
In equation (5), the coefficient µct is the population average cost obtained in the mixture model of
(4), while the coefficients ξt and γt represent respectively the population (marginal) average effective-
ness, and the level of correlation between effectiveness and costs. Notice that these are quantified on
the scale defined by the link function. Thus, in order to estimate the marginal average effectiveness
on the natural scale, it is necessary to compute the inverse transformation µet = g
−1(ξt). To complete
the full Bayesian model, the parameters (ξt, γt) as well as any other nuisance parameter characterising
p(e | c, θt) are given appropriate prior distributions.
Figure 1 shows a graphical representation of the general model structure, highlighting the links
among the three modules. Dashed connections indicate logical relationships among nodes (variables),
while solid connections represent probabilistic relationships or dependence. The three modules are
connected by means of these relationships.
2.4 Economic evaluation
Once the model is fitted to the observed data D, it is possible to directly use the posterior distributions
for (µet, µct) to perform the health economic evaluation. For example, we can construct suitable health
economic summaries, such as the increment in mean effectiveness ∆e := µe1 − µe0 and the increment
in mean cost ∆c := µc1 − µc0.
After having obtained the required posteriors, for instance using an MCMC procedure, one can
post-process the output (e.g. using the R package BCEA [6, 17]) and perform the economic analysis. This
includes constructing the cost-effectiveness plane, which describes the joint distribution of (∆e,∆c),
and the expected incremental benefit EIB = kE[∆e] − E[∆c], which is used to perform the decision
analysis upon deterministically varying the willingness-to-pay threshold k1.
Moreover, it is helpful to conduct a probabilistic sensitivity analysis (PSA), e.g. in terms of the
cost-effectiveness acceptability curve Pr(k∆e − ∆c > 0) and the analysis of the expected value of
information [5, 6], in order to assess the impact of the parameters uncertanty on the decision process.
1The willingness-to-pay k is used to put the cost and effectiveness differentials on the same scale and it represents
the cost that the decision maker is willing to pay to increment the effectiveness measure by one unit. If EIB > 0 then,
for a given k, t = 1 is more cost-effective than t = 0. More details are presented in [1, 2, 3, 4, 5, 6].
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[Zti1] [β1t, . . . , βJt] β0t
[ZtiJ ] πit pt µct µet
dit (ψt0, ψt1) ξt γt
ηt,dit λt,dit φit [τt]
cit eit
Figure 1: A graphical representation of the full Bayesian model accounting for: a) the selection model
for c = 0; b) the marginal model for the costs; and c) the conditional model for the clinical benefit
(given the observed costs). Dashed connections indicate logical relationships, while solid connections
indicate probabilistic relationships. Nodes enclosed in brackets may be not be used: for example, the
covariates Zt1, . . . ,Z
t
J may not be observed and hence the coefficients β1t, . . . , βJt are not included in
the selection model; similarly, the parameter τt may not be needed in the conditional model for e (e.g.
if a Bernoulli distribution is considered, only φit is necessary)
Finally, as different distributional assumptions for the costs may also have an impact on the decision-
making, it is generally advisable to perform a structural sensitivity analysis [18]. Our framework allows
these to be done in a straightforward way.
2.5 Sensitivity to the parameters specification for (ψt1, ζt1)
The choice of the values w and W in the models for (ψt1, ζt1) described above is potentially a delicate
issue, as the results may be sensitive to their specification. In fact, the estimation for the main
parameters (µet, µct) is not really affected by this choice, provided that the encoded relationship
between them really induces ψt1, ζt1 → 0.
It is worth noticing that, as is reasonable, different values for w and W do have an impact on
measures of model fit, such as the Deviance Inflation Criterion (DIC) [19]. This is essentially due to
the fact that the population is really made by two groups, one of which shows costs that are identically
null. Thus, the faster the rate of convergence to 0 for ζt1, the better the fit to the observed data and
therefore the smaller the resulting DIC. But the implications in terms of the resulting estimated values
(and hence the resulting economic model) are immaterial.
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3 Example: acupuncture trial
We consider the RCT conducted in the UK primary care setting to evaluate the cost-effectiveness of
acupuncture in the management of chronic headache, originally presented in [20]. The trial recruited
a total of 401 patients aged 18-65 who reported an average of at least two headaches per month, from
general practices in England and Wales. The participants were randomly allocated to either usual care
(which we indicate with t = 0), or in addition up to 12 acupuncture treatments over three months
from appropriately trained physiotherapists (active intervention, t = 1).
The measure of effectiveness used in the study is the total QALYs gained, obtained using a specific
algorithm based on the SF-6D questionnaire [21]. Only 255 patients (n0 = 119 in the control and
n1 = 136 in the active treatment group) had valid data for the SF-6D questionnaire and thus the
economic evaluation is performed on this sub-sample. Notice that because the time horizon considered
is one year and the SF-6D utility measure is defined in the interval [0; 1], the resulting QALYs for each
individual are also constrained in this interval. The overall cost was calculated for each patient by
adding up the several resources, including non-prescription drugs and private health care visit, visits
to practitioners of complementary or alternative medicine and drug prescriptions.
3.1 Model specification
We follow the framework of section 2 to model the indicator of structural zero cost; however, because
no additional covariate at the individual level is available, we only use the intercept β0t to predict the
probability of zero cost. To make a parallel with the missing data literature, we are then effectively
assuming a mechanism of “zero completely at random” (ZCAR), in which the chance of observing an
individual associated with zero costs does not depend on any other variable2. Of course, this may or
may not be appropriate and typically a less restrictive assumption of “zero at random” (ZAR), under
which the zero pattern depends only on observable covariates (as in Figure 1), will be more tenable.
In order to make the estimation more stable, we model β0t ∼ Cauchy(0, 2.5).
As for the costs, we use both a Gamma and a log-Normal specification, as described in sections
2.2.1 and 2.2.2. In the Gamma model, we set w = 1 and W = 10000, while in the log-Normal model,
we specify w = 1 and W = 50. In both cases, we set Hψ = 1 000 and Hζ = 300; these values encode
the knowledge that the intervention is not particularly expensive, and perform a sensitivity analysis
to the choice of the values for the parameters (w,W ).
2In fact, the correspondence between missing data (MD) and structural zeros (SZ) is not perfect. In MD, the
assumption of missing completely at random (MCAR) implies that the “missingness” and the “outcome” modules are
completely separated (and thus the chance of observing a missing value is assumed to be independent on any other
variable, including the outcome). This implies that under MCAR there is no need to include the missingness module
in the analysis. On the other hand, in SZ the two modules are always linked, because the distribution of the outcome
depends on the zero indicator. Nevertheless, under ZCAR, we are assuming the absence of other (observed or unobserved)
factors that can influence the chance of observing a zero.
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Finally, we model the effectiveness measure using a Beta regression, which in line with [22] we
specify as follows
eit | cit ∼ Beta (φitτt, (1− φit)τt) (6)
logit(φit) = ξt + γt(cit − µct)
ξt, γt, log(τt)
iid
∼ Normal(0, 10 000),
In equation (6), the parameter φit represents the conditional subject-specific average QALYs, while
the parameter τt is the conditional precision (inverse variance), which we assume constant across the
subjects within each treatment arm. The actual measure of effectiveness (i.e. the marginal population
average QALYs under either treatment) can be then retrieved on the correct scale by applying the
inverse logit transformation
µet = g
−1(ξt) =
exp(ξt)
1 + exp(ξt)
.
3.2 Results
We fitted the models of section 3.1 using the R package BCEs0 [23], which implements the general
framework described in section 2 under a set of possible distributional assumptions. In BCEs0, the user
needs to: i) specify a data list including the observed values for (e, c) under the two treatment options
and possibly the matrices including the values for the covariatesXt1, . . . ,X
t
J , and the fixed parameters
Hψ and Hζ ; ii) select a distribution for the costs (implemented choices are Gamma, log-Normal
and Normal); and iii) select a distribution for the measure of effectiveness (Beta, Bernoulli, Gamma
and Normal are currently implemented). BCEs0 will then write the JAGS [24] model for the selected
specification to a text file, call the library R2jags [25] (which connects JAGS to R in background) and
perform the MCMC analysis. The resulting simulations from the posterior distributions are saved to
the R workspace and can be used for the health economic evaluation. Since the model file is saved in
the working directory, the user can use it as a template and modify.
We ran 10 000 iterations, using a burn-in of 5 000 and retaining one iteration every 10, which
resulted in a sample of 1 000 iterations which we used to produce the posterior analysis. For each
variable in the model, convergence of the MCMC sampler was assessed by the analysis of the potential
scale reduction [26], as well as the effective sample size.
Table 1 presents summary statistics from the posterior distributions of the main parameters in the
model, for both specifications of the cost variable. In both models, treatment t = 1 is associated with
both higher costs and higher QALYs, on average. In particularly, the average costs is substantially
larger for this arm of the trial. As is possible to see, for both treatments there is a significant difference
between µct, the overall average cost and ψt0, the average cost for the subjects in D
pos
t . The log-Normal
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model produces estimations of the costs that are slightly lower than those produced by the Gamma
specification.
Table 1: Posterior summaries for selected parameters for the Gamma/Beta and log-Normal/Beta
models
Gamma/Beta model log-Normal/Beta model
Parameter Mean SD 95% interval Mean SD 95% interval
p0 0.039 0.018 0.012 0.080 0.038 0.019 0.011 0.080
ψ00 226.958 20.885 187.075 267.431 179.934 11.916 155.702 201.788
µc0 218.150 20.520 176.721 259.649 173.071 11.830 148.505 195.024
µe0 0.710 0.011 0.688 0.731 0.712 0.010 0.691 0.731
p1 0.011 0.009 0.001 0.036 0.011 0.009 0.001 0.032
ψ10 408.171 21.213 365.324 449.598 393.165 18.378 357.348 428.717
µc1 403.823 21.411 361.115 445.206 378.179 18.972 341.202 415.554
µe1 0.729 0.011 0.708 0.750 0.731 0.011 0.710 0.751
Of course, in a real-life, comprehensive analysis, sensitivity to the choice of the distribution for the
parameters of each model should be explored extensively. Incidentally, the values for the willingness
to pay parameter k beyond which EIB > 0 for the two different specifications of the model are quite
similar (£9 754 and £10 713 for the Gamma/Beta and the log-Normal/Beta models, respectively) and
so are the results of PSA. Thus, the practical implications of the resulting differences would not be
particularly relevant in this case, as the active intervention would be considered as cost-effective and
sustainable for the NHS under both specifications.
We have run the models using different values for the parameters w,W , to assess the impact on the
actual cost estimation. As an example, Figure 2 shows the results of the sensitivity analysis onW , hold-
ing w fixed to 1 for all cases; in particular, we have selected values ofW = (10, 100, 1 000, 10 000, 100 000).
In the graph, we report the posterior mean and both a 50% and a 95% posterior credible interval for
the average costs (the dark and light lines, respectively). The results for t = 0 are depicted on the left
side, while those for t = 1 are on the right side. As is possible to see, the point as well as the interval
estimate of the average costs are effectively unchanged in all the cases.
It is interesting to notice that model fitting (as measured in terms of the DIC) varies differently
for the Gamma and the log-Normal model. In the former, the DIC becomes smaller when W increases
and, although there are no practical differences in terms of the estimation for all the parameters, the
best-fitting model is the one with W = 100 000, although the results are hardly different for all the
parameters.
Conversely, for the log-Normal specification, the best-fitting model is the one withW = 10; however,
convergence is not really achieved in this case, particularly for the coefficient β01, which estimates the
chance of zero cost for t = 1. In the absence of additional information, the model effectively computes
a marginal average probability based only of the observed data (and no other covariate). But since the
11
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Figure 2: Sensitivity analysis for the choice of the parameter W . The dots represent the posterior
means for the estimated costs µc0 and µc1 (on the left and the right of the panel, respectively). The
light dark and lines indicate the 50% and 95% credible intervals, respectively. Dots and lines in red
indicate the Gamma model, while those in blue indicate the log-Normal model. Within models, in all
cases the results are substantially identical and do not depend at all on the selected value of W
observed proportion is very close to 0, the estimations are unstable when W is not large enough. We
reiterate that this has a meaningful implication on the model convergence, but not on the estimated
costs and effectiveness, and hence on the health economic evaluation. A value of W = 50 (which is
used by default in BCEs0) is sufficient to provide convergence and model fit.
4 Discussion
In this paper we have defined and discussed a general framework to handle cost-effectiveness analysis
using individual level data (e.g. from a RCT) in the presence of structural zeros in the cost variable.
This is a challenging situation because cost-effectiveness models are characterised by a relatively com-
plex structure which require the formal inclusion of correlation between the outcomes. In addition,
because of asymmetry in the cost distributions, we also need to model them using suitable formulations.
The framework developed in section 2 uses of a flexible structure and allows the two components
of the cost distributions to be modelled using a single specification. The parameters of the cost
distributions are defined differently in the two components of the mixture; for the subjects with
observed null costs, the specification implies that the final estimation is identically 0. Consequently,
the final estimation of the overall population mean costs is a weighted average of the two components.
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The correlation between costs and clinical benefits is ensured by the model strucure.
The choice of the selection model for c > 0 is of course crucial. In the example of section 3, we have
assumed that no unobserved factors impact on the probability of an individual generating null costs.
This is in general a very restrictive assumption and in fact it is likely that, even in a randomisation
context, the probability πit does depend on some covariates and, possibly, is also affected by unobserved
confounders. In general, this complicates the situation, but the generalisability of the framework is
not compromised, as the model in (1) can be extended to deal with more complex situations.
The R package BCEs0 can be used, at least as a first approximation, to build a model consistent with
the general framework. The choice of possible distributions for (e, c) is limited to what we consider
to be the most likely situations. However, a translation into the JAGS language (which is effectively
identical when applied to other software such as OpenBUGS) is automatically generated. Thus, the user
can easily modify the “template” model file to cater for their specific needs (e.g. adding a different
distribution for e | c, including structured effects in the selection model, or modifying the priors).
Unlike simpler but less efficient solutions to the problem of structural zeros in cost-effectiveness
analysis, the structure of section 2 is quite robust to the choice of the relevant parameters. In particular,
it is pretty easy to ensure that the null component of the mixture for the cost distributions is indeed
identically 0. As showed in the acupuncture trial example, the choice of the parameters w,W is
effectively irrelevant, provided that the mean and variances for the distribution under θnullt tend to
zero sufficiently quickly.
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